Loading clinical trials...
Loading clinical trials...
A 6-Week, Prospective, Randomized, Double-Blind, Double-Dummy Phase IV Clinical Trial Designed to Evaluate the Efficacy of an Aggressive Multi-Risk Factor Management Strategy With Caduet (A3841045) Versus a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensive Subjects With Additional Risk Factors.
Conditions
Interventions
Amlodipine besylate
Amlodipine besylate/atorvastatin calcium single pill combination
+2 more
Locations
51
United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Mesa, Arizona, United States
Pfizer Investigational Site
Garden Grove, California, United States
Pfizer Investigational Site
Mission Viejo, California, United States
Start Date
January 1, 2007
Primary Completion Date
April 1, 2008
Completion Date
April 1, 2008
Last Updated
February 11, 2021
NCT06647511
NCT05746039
NCT07439939
NCT07218029
NCT07098065
NCT06741436
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions